These studies indicate that FXR-gut microbiome-TGR5/GLP-1 signaling cascade represents a major mechanism underlying fexaramine-mediated beneficial effects on NAFLD and metabolic diseases. This evidence concerns the gene GPBAR1 and metabolic disease.